ArticleBMC gastroenterology2025
Analysis of risk factors for Clostridioides difficile infection in patients with ulcerative colitis and development of a predictive nomogram.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to identify the risk factors associated with Clostridioides difficile infection (CDI) in patients with ulcerative colitis (UC) and to develop a predictive nomogram.
methodsWe prospectively enrolled 331 UC patients from April 2022 to October 2024. We randomly assigned them to a training set (n = 232) and a validation set (n = 99) in a 7:3 ratio. In the training set, there were 51 patients had CDI (CDI group) and 181 patients did not (non-CDI group). Clinical data were recorded. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to screen risk factors for CDI in UC patients. R software was used to construct a nomogram model for predicting CDI. The calibration curve evaluated the model's calibration, while Receiver operating characteristic (ROC) curve assessed its discriminative power. Clinical decision curve analysis was conducted to evaluate clinical utility.
resultsAge, obesity prevalence, and use of infliximab and glucocorticoids were higher in the CDI group compared to the non-CDI group, and albumin levels were lower (P < 0.05). Increased age, obesity, use of infliximab and glucocorticoids, and decreased albumin were independent risk factors for UC with CDI (P < 0.05). The training and validation sets showed that the calibration curve fitted well with the ideal curve, and the area under the ROC curve (AUC) was 0.930 and 0.877, respectively, indicating good calibration and discrimination. Clinical decision curve analysis showed high clinical effectiveness.
conclusionThe proposed nomogram demonstrated excellent performance in predicting CDI risk among patients with UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.